Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Lyra Therapeutics
(NASDAQ:LYRA)
Intraday
$5.31
-0.095
[-1.76%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$5.31
-0.095
[-1.76%]
Last update: 11:26AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Lyra Therapeutics Stock (NASDAQ:LYRA)
Lyra Therapeutics Stock (NASDAQ: LYRA)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 17, 2024
Cantor Fitzgerald Reiterates Overweight on Lyra Therapeutics
Benzinga Newsdesk
-
1 day ago
Monday, March 25, 2024
B of A Securities Maintains Buy on Lyra Therapeutics, Lowers Price Target to $11
Benzinga Newsdesk
-
Mar 25, 2024, 6:47AM
Friday, March 22, 2024
HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target
Benzinga Newsdesk
-
Mar 22, 2024, 6:40AM
Tuesday, November 14, 2023
Executive Chair of Lyra Therapeutics Purchased $74K In Stock
Benzinga Insights
-
Nov 14, 2023, 10:02AM
Friday, October 06, 2023
What 4 Analyst Ratings Have To Say About Lyra Therapeutics
Benzinga Insights
-
Oct 6, 2023, 11:00AM
BTIG Assumes Lyra Therapeutics at Buy, Announces Price Target of $15
Benzinga Newsdesk
-
Oct 6, 2023, 10:23AM
Monday, October 02, 2023
HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target
Benzinga Newsdesk
-
Oct 2, 2023, 7:03AM
Tuesday, September 12, 2023
B of A Securities Maintains Buy on Lyra Therapeutics, Raises Price Target to $15
Benzinga Newsdesk
-
Sep 12, 2023, 10:58AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Sep 12, 2023, 9:06AM
Lyra Therapeutics shares are trading higher after the company announced its BEACON Phase 2 study of LYR-220 for chronic rhinosinusitis in patients with prior ethmoid sinus surgury met its primary endpoint.
Benzinga Newsdesk
-
Sep 12, 2023, 8:56AM
Market-Moving News for September 12th
Benzinga Newsdesk
-
Sep 12, 2023, 8:35AM
Lyra Therapeutics Shares Resume Trade
Bill Haddad
-
Sep 12, 2023, 7:32AM
Lyra Therapeutics' BEACON Phase 2 Study Of LYR-220 For Chronic Rhinosinusitis In Patients With Prior Ethmoid Sinus Surgery Met Its Primary Endpoint
Benzinga Newsdesk
-
Sep 12, 2023, 7:03AM
Thursday, August 31, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
Benzinga Insights
-
Aug 31, 2023, 11:00AM
HC Wainwright & Co. Initiates Coverage On Lyra Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk
-
Aug 31, 2023, 6:24AM
Tuesday, August 29, 2023
Lyra Therapeutics Announced That The Pivotal Phase 3 ENLIGHTEN I Trial Of Lyr-210 In Adult Patients With Chronic Rhinosinusitis Who Have Not Had Prior Ethmoid Sinus Surgery, Is Fully Enrolled. Topline Results Are Expected In 1H Of 2024 As Planned
Benzinga Newsdesk
-
Aug 29, 2023, 7:10AM
Thursday, July 13, 2023
Lyra Therapeutics President & CEO Awarded $468K Worth of Stock Options
Benzinga Insights
-
Jul 13, 2023, 11:01AM
Tuesday, June 27, 2023
Lyra Therapeutics President & CEO Awarded $610K Worth of Stock Options
Benzinga Insights
-
Jun 27, 2023, 11:02AM
Tuesday, June 20, 2023
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jun 20, 2023, 1:07PM
Friday, May 26, 2023
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
May 26, 2023, 9:06AM
Lyra Therapeutics Announces $50M Private Placement
Benzinga Newsdesk
-
May 26, 2023, 8:04AM
Lyra Therapeutics Plans $50M Private Placement
Benzinga Newsdesk
-
May 26, 2023, 7:59AM
Friday, May 12, 2023
Lyra Therapeutics: Q1 Earnings Insights
Benzinga Insights
-
May 12, 2023, 8:55AM
Lyra Therapeutics Q1 EPS $(0.44) Up From $(0.92) YoY, Sales $410.00K Down From $468.00K YoY
Benzinga Newsdesk
-
May 12, 2023, 7:03AM
Tuesday, April 25, 2023
Lyra Therapeutics Has Resumed Screening And Enrollment In ENLIGHTEN II, Its Second Pivotal Phase 3 Trial Of LYR-210 In Patients With Chronic Rhinosinusitis
Benzinga Newsdesk
-
Apr 25, 2023, 8:10AM
Thursday, March 30, 2023
Lyra Therapeutics's Return On Capital Employed Insights
Benzinga Insights
-
Mar 30, 2023, 10:47AM
Lyra Therapeutics Q4 EPS $(0.32) Beats $(0.41) Estimate, Sales $11.00K Miss $150.00K Estimate
Happy Mohamed
-
Mar 30, 2023, 1:12AM
Monday, March 27, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Mar 27, 2023, 1:22PM
Tuesday, February 07, 2023
BTIG Maintains Buy on Lyra Therapeutics, Lowers Price Target to $20
Benzinga Newsdesk
-
Feb 7, 2023, 9:36AM
Monday, February 06, 2023
Lyra Therapeutics Completes Enrollment In BEACON Phase 2 Clinical Trial Of LYR-220 In Post-Surgical Chronic Rhinosinusitis Patients
Bill Haddad
-
Feb 6, 2023, 7:56AM
Monday, December 19, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Dec 19, 2022, 12:40PM
Monday, December 12, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Dec 12, 2022, 10:50AM
Thursday, December 08, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Dec 8, 2022, 12:33PM
Wednesday, November 30, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Nov 30, 2022, 10:34AM
Tuesday, November 08, 2022
Lyra Therapeutics Q3 EPS $(0.40) Up From $(0.85) YoY, Sales $359.00K Up From $14.00K YoY
Benzinga Newsdesk
-
Nov 8, 2022, 4:54PM
Wednesday, October 26, 2022
Lyra Therapeutics Says Concluded There Is Material Weakness In Internal Control Over Financial Reporting Related To Accounting For Certain Complex, Nonrecurring Transactions
Michael Horton
-
Oct 26, 2022, 5:22PM
Audit Committee Of Lyra Therapeutics Board Says Prior Q1, Q2 Financial Statements Should No Longer Be Relied Upon, Says Intends To Restate Prior Financial Statements
Michael Horton
-
Oct 26, 2022, 5:21PM
Tuesday, September 13, 2022
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Ragothaman Srinivasan
-
Sep 13, 2022, 6:45PM
Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
Ragothaman Srinivasan
-
Sep 13, 2022, 9:56AM
Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial Of LYR-220 In Post-Surgical Chronic Rhinosinusitis Patients To Randomized Stage Of Study
Bill Haddad
-
Sep 13, 2022, 7:01AM
Thursday, September 08, 2022
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Ragothaman Srinivasan
-
Sep 8, 2022, 6:17PM
Lyra Therapeutics Announces First Patient Enrolled In Pivotal ENLIGHTEN II Clinical Trial Of LYR-210 In Chronic Rhinosinusitis Patients
Benzinga Newsdesk
-
Sep 8, 2022, 7:01AM
Friday, September 02, 2022
Lyra Therapeutics's Return On Capital Employed Overview
Benzinga Insights
-
Sep 2, 2022, 10:32AM
Tuesday, August 09, 2022
Lyra Therapeutics: Q2 Earnings Insights
Benzinga Insights
-
Aug 9, 2022, 9:05AM
Lyra Therapeutics Q2 EPS $(0.43) Up From $(0.85) YoY
Benzinga Newsdesk
-
Aug 9, 2022, 7:29AM
Monday, July 18, 2022
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Jul 18, 2022, 5:48PM
Friday, June 10, 2022
Lyra Therapeutics's Return On Capital Employed Insights
Benzinga Insights
-
Jun 10, 2022, 11:42AM
Wednesday, May 25, 2022
Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor
Vandana Singh
-
May 25, 2022, 1:07PM
Tuesday, May 24, 2022
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022
Benzinga Insights
-
May 24, 2022, 10:04AM
Cantor Fitzgerald Initiates Coverage On Lyra Therapeutics with Overweight Rating, Announces Price Target of $15
Benzinga Newsdesk
-
May 24, 2022, 6:55AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch